Bill > H978

This bill aims to promote healthcare access and affordability for patients. It has two key provisions: 1. It requires health insurance carriers to make available at least 80% of the estimated rebates they receive from pharmaceutical manufacturers, pharmacies, or other parties to reduce the amount of cost-sharing charged to insured patients at the point of sale. Carriers are not responsible for any difference between the estimated and actual rebate amounts, as long as the estimates were calculated in good faith. 2. It requires the Health Policy Commission and the Secretary of Health and Human Services to conduct an analysis and issue a report on the future of cell and gene therapy in Massachusetts. The report must assess any potential barriers to access for MassHealth beneficiaries and other vulnerable populations, and propose corrective policy solutions, including potential modifications to MassHealth reimbursement methodologies if needed to address any identified disparities. The bill aims to increase transparency around prescription drug rebates and ensure greater affordability and access to emerging cell and gene therapies for patients covered by public and private insurance plans.

Business and Industry, Health and Social Services

https://malegislature.gov/Bills/193/H978